Kamar Nassim, Rostaing Lionel, Selves Janick, Sandres-Saune Karine, Alric Laurent, Durand Dominique, Izopet Jacques
Department of Nephrology, Dialysis and Multiorgan Transplantation, CHU Rangueil, Toulouse, Paris, France.
Am J Transplant. 2005 Jul;5(7):1704-12. doi: 10.1111/j.1600-6143.2005.00918.x.
The aim of our study was to assess hepatitis C virus (HCV) evolution and long-term liver histology outcome in anti-HCV(+)/RNA(+) renal transplant (RT) patients. A total of 51 anti-HCV(+)/RNA(+) RT patients underwent liver biopsies (LB) every 3-4 years after transplantation (two LBs, n = 51; three LBs, n = 42; four LBs, n = 9). The hypervariable region (HVR)-1 of the HCV genome from all patients was characterized over time. Overall, the rate of liver fibrosis progression was 0.09 +/- 0.03 Metavir units/year. We identified three groups of patients: those in whom liver fibrosis remained stable (n = 21), those with progressing liver fibrosis (n = 21) and those with a regression in liver fibrosis (n = 10). In the last two groups, the progression and the regression of liver fibrosis were gradual during follow-up. Ferritin levels and hepatosiderosis were significantly higher in fibrosers. Initial fibrosis stage and high diversification of the HVR-1 of HCV genome between transplantation and the first liver biopsy were independent factors associated with liver fibrosis regression. In conclusion, in the current study, more than 10 years after renal transplantation, HCV infection was not harmful upon liver histology in more than 50% of patients. The diversification of the HVR-1 might be used to predict liver fibrosis outcome.
我们研究的目的是评估抗丙型肝炎病毒(HCV)阳性/RNA阳性的肾移植(RT)患者的HCV演变及长期肝脏组织学转归。共有51例抗HCV阳性/RNA阳性的RT患者在移植后每3 - 4年接受一次肝活检(LB)(两次肝活检,n = 51;三次肝活检,n = 42;四次肝活检,n = 9)。对所有患者HCV基因组的高变区(HVR)-1随时间进行特征分析。总体而言,肝纤维化进展速率为0.09±0.03梅塔维单位/年。我们将患者分为三组:肝纤维化保持稳定的患者(n = 21)、肝纤维化进展的患者(n = 21)和肝纤维化逆转的患者(n = 10)。在最后两组中,肝纤维化的进展和逆转在随访期间是渐进的。纤维化患者的铁蛋白水平和肝铁沉积明显更高。移植与首次肝活检之间的初始纤维化阶段以及HCV基因组HVR - 1的高度多样化是与肝纤维化逆转相关的独立因素。总之,在本研究中,肾移植10多年后,超过50%的患者中HCV感染对肝脏组织学无害。HVR - 1的多样化可能用于预测肝纤维化转归。